272 related articles for article (PubMed ID: 32056720)
1. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease.
Mahler DA
Respir Med; 2020 Jan; 161():105857. PubMed ID: 32056720
[TBL] [Abstract][Full Text] [Related]
2. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
[TBL] [Abstract][Full Text] [Related]
3. FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.
González-Torralba F; Baloira A; Abad A; Fuster A; García-Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL
Int J Chron Obstruct Pulmon Dis; 2022; 17():1005-1015. PubMed ID: 35547784
[TBL] [Abstract][Full Text] [Related]
4. The Repeatability of Inspiration Performance Through Different Inhalers in Patients with Chronic Obstructive Pulmonary Disease and Control Volunteers.
Erdelyi T; Lazar Z; Odler B; Tamasi L; Müller V
J Aerosol Med Pulm Drug Deliv; 2020 Oct; 33(5):271-281. PubMed ID: 32460588
[No Abstract] [Full Text] [Related]
5. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease.
Mahler DA
Ann Am Thorac Soc; 2017 Jul; 14(7):1103-1107. PubMed ID: 28481631
[TBL] [Abstract][Full Text] [Related]
6. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
Altman P; Wehbe L; Dederichs J; Guerin T; Ament B; Moronta MC; Pino AV; Goyal P
BMC Pulm Med; 2018 Jun; 18(1):100. PubMed ID: 29898702
[TBL] [Abstract][Full Text] [Related]
7. Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.
Lavorini F; Mannini C; Chellini E; Fontana GA
Drugs Aging; 2016 Jul; 33(7):461-73. PubMed ID: 27216613
[TBL] [Abstract][Full Text] [Related]
8. Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD.
Mahler DA; Halpin DMG
Chest; 2021 Aug; 160(2):491-498. PubMed ID: 33812852
[TBL] [Abstract][Full Text] [Related]
9. Optimising inhaler technique in chronic obstructive pulmonary disease: a complex issue.
Riley J; Krüger P
Br J Nurs; 2017 Apr; 26(7):391-397. PubMed ID: 28410043
[TBL] [Abstract][Full Text] [Related]
10. Patient Inspiratory Maneuver Performance; Peak Lungpower, Acceleration and Volume.
Haikarainen J; Vahteristo M; Lähelmä S; Vartiainen V; Malmberg LP
J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):305-313. PubMed ID: 32423277
[No Abstract] [Full Text] [Related]
11. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.
Sorino C; Negri S; Spanevello A; Visca D; Scichilone N
Eur J Intern Med; 2020 May; 75():15-18. PubMed ID: 32113944
[TBL] [Abstract][Full Text] [Related]
12. Inhaled drug delivery in the hands of the patient.
Lavorini F
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):414-8. PubMed ID: 25238005
[TBL] [Abstract][Full Text] [Related]
13. Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD.
Jõgi R; Mattila L; Vahteristo M; Takala A; Lähelmä S; Vartiainen VA; Lindqvist A
Int J Chron Obstruct Pulmon Dis; 2021; 16():1193-1201. PubMed ID: 33958863
[TBL] [Abstract][Full Text] [Related]
14. Optimizing drug delivery in COPD: The role of inhaler devices.
Rogliani P; Calzetta L; Coppola A; Cavalli F; Ora J; Puxeddu E; Matera MG; Cazzola M
Respir Med; 2017 Mar; 124():6-14. PubMed ID: 28284323
[TBL] [Abstract][Full Text] [Related]
15. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.
Ghosh S; Ohar JA; Drummond MB
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):381-387. PubMed ID: 28933581
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients.
Harb HS; Laz NI; Rabea H; Abdelrahim MEA
Eur J Pharm Sci; 2020 Apr; 147():105298. PubMed ID: 32151707
[TBL] [Abstract][Full Text] [Related]
17. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Cavalli F; Usmani OS; Rogliani P
Expert Opin Drug Deliv; 2020 May; 17(5):635-646. PubMed ID: 32130023
[No Abstract] [Full Text] [Related]
18. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
Henriet AC; Marchand-Adam S; Mankikian J; Diot P
Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
[TBL] [Abstract][Full Text] [Related]
19. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
20. Demystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care.
Capstick TGD; Gudimetla S; Harris DS; Malone R; Usmani OS
Clin Drug Investig; 2024 Feb; 44(2):109-114. PubMed ID: 38198116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
